Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Apr 29, 2023--

Related Keywords

Chicago ,Illinois ,United States ,Italy ,Milan ,Lombardia ,Evanston ,United Kingdom ,Germany ,Munich ,Bayern ,American ,Briant Helfand ,Mike Beyer ,Priscilla Harlan ,Clare Gidley ,Scintomics Gmb ,Davide Gauden ,Division Of Urology ,Technical University Of Munich ,Nuclear Medicine ,American Urological Association ,Drug Administration ,Study Group ,Corporate Communications ,Sam Brown Inc ,Bracco Group ,Northshore University Healthsystem ,Earth Diagnostics ,Detection Rates ,Prostate Specific Antigen ,Prostate Specific Membrane Antigen Targeted ,Business Wire ,New Drug Application ,Chief Executive Officer ,Blue Earth ,Blue Earth Diagnostic ,Prostate Cancer Following Primary Treatment ,Radiation Therapy ,Radiohybrid Prostate Specific Membrane Antigen ,Technical University ,Blue Earth Diagnostics ,Scintomics Gmbh ,Earth Diagnostic ,Bracco Imaging ,Interventional Radiology ,Cardiac Catheterization ,Magnetic Resonance Imaging ,Contrast Enhanced Ultrasound ,Blue Earth Therapeutics ,For Blue Earth Diagnostics ,Director Marketing ,